Photocrosslinkable Liver Extracellular Matrix Hydrogels for the Generation of 3D Liver Microenvironment Models

Scientists explored the efficacy of two protocols to decellularize porcine liver tissue using varying combinations of commonly used chemical agents such as Triton X-100, Sodium Dodecyl Sulphate and ammonium hydroxide.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

Share

Multi-Disciplinary Clinic Models: A Paradigm of Care for Management of Non-alcoholic Fatty Liver Disease (NAFLD)

Scientists review current models of multidisciplinary care teams and introduce a framework for building a comprehensive NAFLD program based on real-world experience within their institution.
[Hepatology]
Abstract
Bookmark

No account yet? Register

Share

Metabolic Hallmarks of Liver Regeneration

The authors highlight how lipids, carbohydrates, and proteins dynamically change and orchestrate liver regeneration. They discuss translational studies in which metabolic intervention has been used to treat chronic liver diseases.
[Trends in Endocrinology and Metabolism]
Abstract
Bookmark

No account yet? Register

Share

The Immunological and Metabolic Landscape in Primary and Metastatic Liver Cancer

Researchers discuss how the hepatic microenvironment adapts to pathologies characterized by chronic inflammation and metabolic alterations. They illustrate how these immunological or metabolic changes alter immunosurveillance and thus hinder or promote the development of primary liver cancer.
[Nature Reviews Cancer]
Abstract
Bookmark

No account yet? Register

Share

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from US FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

Arrowhead Pharmaceuticals, Inc. announced that it was granted Breakthrough Therapy designation by the US FDA for ARO-AAT, also known as TAK-999, the company’s second-generation investigational RNA interference therapeutic being co-developed with Takeda Pharmaceutical Company Limited as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
[Arrowhead Pharmaceuticals, Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

Share

Downregulation of TMEM220 Promotes Tumor Progression in Hepatocellular Carcinoma

Through overexpressing TMEM220 in hepatocellular carcinoma cell lines, scientists found that the proliferation of cancer cells was significantly slowed down and metastasis was significantly reduced.
[Cancer Gene Therapy]
Abstract
Bookmark

No account yet? Register

Share

Super Enhancer Regulation of Cytokine-Induced Chemokine Production in Alcoholic Hepatitis

Researchers explored the mechanistic role of super-enhancers linking cytokine TNFα with chemokine amplification in alcoholic hepatitis.
[Nature Communications]
Full Article
Bookmark

No account yet? Register

Share

TRIB2 Desensitizes Ferroptosis via βTrCP-Mediated TFRC Ubiquitiantion in Liver Cancer Cells

Scientists identified the role of tribbles homolog 2 (TRIB2) to relieve oxidative damage via reducing the availability of ubiquitin that was essential for the ubiquitination and subsequent degradation of glutathione peroxidase 4.
[Cell Death Discovery]
Full Article
Bookmark

No account yet? Register

Share

Low Serum Magnesium Concentration Is Associated with the Presence of Viable Hepatocellular Carcinoma Tissue in Cirrhotic Patients

In a subset of 94 patients with hepatocellular carcinoma (HCC), a linear mixed effects model adjusted for confounders showed that serum Mg at diagnosis of HCC was lower than before diagnosis of the tumor.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

Share

BH3-Only Protein Expression Determines Hepatocellular Carcinoma Response to Sorafenib-Based Treatment

In the presence of NOXA, BIM-deficient hepatocellular carcinoma cells could be in turn strongly sensitized for cell death induction by the combination of sorafenib with TNF-related apoptosis-inducing ligand .
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

Share

SMYD3 Promotes Hepatocellular Carcinoma Progression by Methylating S1PR1 Promoters

Researchers reported that SET and MYND domain-containing protein 3 (SMYD3) expression in hepatocellular carcinoma (HCC) was an independent prognostic factor for survival and promoted the proliferation and migration of HCC cells.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

Share
Share